Have a feature idea you'd love to see implemented?
Let us know!
DRRX Durect Corp
Price (delayed)
$0.95
Market cap
$29.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.52
Enterprise value
$34.14M
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic
Highlights
The debt has declined by 41% year-on-year and by 14% since the previous quarter
The EPS has soared by 66% year-on-year but it is down by 6% since the previous quarter
The net income has soared by 53% YoY but it has contracted by 8% from the previous quarter
Durect's equity has plunged by 92% YoY and by 76% from the previous quarter
The company's quick ratio fell by 48% YoY and by 26% QoQ
Key stats
What are the main financial stats of DRRX
Market
Valuations
Earnings
Shares outstanding
31.04M
Market cap
$29.49M
Enterprise value
$34.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
24.23
Price to sales (P/S)
3.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.97
Revenue
$8.59M
Gross profit
$6.78M
Net income
-$17.07M
EBIT
-$15.11M
EBITDA
-$15.17M
Free cash flow
-$21.81M
Per share
Balance sheet
Liquidity
EPS
-$0.52
EPS diluted
-$0.64
Free cash flow per share
-$0.7
Book value per share
$0.04
Revenue per share
$0.28
TBVPS
$0.58
Total assets
$24.07M
Total liabilities
$22.85M
Debt
$13.74M
Equity
$1.22M
Working capital
-$5.78M
Debt to equity
11.29
Current ratio
0.71
Quick ratio
0.56
Net debt/EBITDA
-0.31
Margins
Efficiency
Dividend
EBITDA margin
-176.5%
Gross margin
78.9%
Net margin
-198.6%
Operating margin
-225.1%
Return on assets
-50.5%
Return on equity
-232.7%
Return on invested capital
-454.2%
Return on capital employed
-391.7%
Return on sales
-175.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DRRX stock price
How has the Durect stock price performed over time
Intraday
10.72%
1 week
26.67%
1 month
5.14%
1 year
89.24%
YTD
61.02%
QTD
-29.1%
Financial performance
How have Durect's revenue and profit performed over time
Revenue
$8.59M
Gross profit
$6.78M
Operating income
-$19.34M
Net income
-$17.07M
Gross margin
78.9%
Net margin
-198.6%
The company's operating income has surged by 54% YoY and by 22% QoQ
The net income has soared by 53% YoY but it has contracted by 8% from the previous quarter
DRRX's operating margin has soared by 51% YoY and by 24% QoQ
The net margin has surged by 50% year-on-year but it has declined by 6% since the previous quarter
Growth
What is Durect's growth rate over time
Valuation
What is Durect stock price valuation
P/E
N/A
P/B
24.23
P/S
3.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.97
The EPS has soared by 66% year-on-year but it is down by 6% since the previous quarter
DRRX's P/B is 142% above its 5-year quarterly average of 10.0 and 102% above its last 4 quarters average of 12.0
Durect's equity has plunged by 92% YoY and by 76% from the previous quarter
The price to sales (P/S) is 72% lower than the 5-year quarterly average of 12.2 and 14% lower than the last 4 quarters average of 4.0
The revenue has declined by 7% year-on-year but it has grown by 2.2% since the previous quarter
Efficiency
How efficient is Durect business performance
Durect's ROE has plunged by 57% from the previous quarter but it has increased by 4.4% YoY
The ROS has soared by 52% year-on-year but it is down by 10% since the previous quarter
Durect's return on invested capital has increased by 42% QoQ
Durect's ROA has decreased by 33% from the previous quarter but it has increased by 24% YoY
Dividends
What is DRRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DRRX.
Financial health
How did Durect financials performed over time
The total assets is 5% more than the total liabilities
The total assets has plunged by 56% YoY and by 19% from the previous quarter
The company's quick ratio fell by 48% YoY and by 26% QoQ
Durect's equity has plunged by 92% YoY and by 76% from the previous quarter
The debt has declined by 41% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.